2. GPCR/G Protein PI3K/Akt/mTOR Epigenetics
  3. Adenosine Receptor PI3K Akt Epigenetic Reader Domain
  4. N6-Cyclohexyladenosine

N6-Cyclohexyladenosine  (Synonyms: CHA)

Cat. No.: HY-18939 Purity: 99.76%
SDS
COA
Handling Instructions Technical Support

N6-Cyclohexyladenosine is a selective adenosine A1 receptor agonist (EC50 = 8.2 nM). N6-Cyclohexyladenosine enhances the activation of the PI3K/Akt/CREB/BDNF axis. N6-Cyclohexyladenosine promotes remyelination, induces sleep, and improves 3-NP-induced Huntington's disease. N6-Cyclohexyladenosine can be used in liver cancer research.

For research use only. We do not sell to patients.

N6-Cyclohexyladenosine Chemical Structure

N6-Cyclohexyladenosine Chemical Structure

CAS No. : 36396-99-3

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
5 mg In-stock
10 mg In-stock
50 mg In-stock
100 mg   Get quote  
200 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 2 publication(s) in Google Scholar

N6-Cyclohexyladenosine Related Antibodies

Top Publications Citing Use of Products

View All Adenosine Receptor Isoform Specific Products:

View All Isoforms
Adenosine A1 receptor (A1R) Adenosine A2A receptor (A2AR) Adenosine A2B receptor (A2BR) Adenosine A3 receptor (A3R)

View All PI3K Isoform Specific Products:

View All Isoforms
PI3Kα PI3Kβ PI3Kγ PI3Kδ PI3KC2α PI3KC2β PI3KC2γ Vps34 PI3K PI3KC3 p120γ

View All Akt Isoform Specific Products:

View All Isoforms
Akt Akt1 Akt2 Akt3

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

N6-Cyclohexyladenosine is a selective adenosine A1 receptor agonist (EC50 = 8.2 nM). N6-Cyclohexyladenosine enhances the activation of the PI3K/Akt/CREB/BDNF axis. N6-Cyclohexyladenosine promotes remyelination, induces sleep, and improves 3-NP-induced Huntington's disease. N6-Cyclohexyladenosine can be used in liver cancer research[1][2][3][4][5][6][7].

Cellular Effect
Cell Line Type Value Description References
Caco-2 GI50
> 250 μM
Compound: 16, CHA
Antitumor activity against human CaCo2 cells after 48 hrs by MTS assay
Antitumor activity against human CaCo2 cells after 48 hrs by MTS assay
[PMID: 18588281]
HT-29 GI50
> 250 μM
Compound: 16, CHA
Antitumor activity against human HT29 cells after 48 hrs by MTS assay
Antitumor activity against human HT29 cells after 48 hrs by MTS assay
[PMID: 18588281]
K562 GI50
> 250 μM
Compound: 16, CHA
Antitumor activity against human K562 cells after 48 hrs by MTS assay
Antitumor activity against human K562 cells after 48 hrs by MTS assay
[PMID: 18588281]
MCF7 GI50
> 250 μM
Compound: 16, CHA
Antitumor activity against human MCF7 cells after 48 hrs by MTS assay
Antitumor activity against human MCF7 cells after 48 hrs by MTS assay
[PMID: 18588281]
In Vitro

N6-Cyclohexyladenosine reduces the extent of demyelination and promote remyelination in rat optic chiasm[1].
N6-Cyclohexyladenosine (10 nM-50 μM; 20 h) significantly increases the secretion of Erythropoietin in human hepatoma cell line Hep 3B under hypoxic conditions[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

N6-Cyclohexyladenosine Related Antibodies
In Vivo

N6-Cyclohexyladenosine (2 μL, 1%; injected inside the right lateral ventricle; administered daily during the demyelination phase (days 0-13) or the remyelination phase (days 14-27)) in a rat optic chiasm demyelination model can reduce the extent of demyelination, promote remyelination, and improve visual evoked potential-related indicators[1].
N6-Cyclohexyladenosine (10-100 μM; infused into the basal forebrain via a microdialysis probe) can induce sleep in a rat model of basal forebrain cholinergic neuron injury [2].
N6-Cyclohexyladenosine (60 μg/kg; i.p.) is a potent locomotor depressant in mice[3].
N6-Cyclohexyladenosine (6.25 nM/1 μL; intrastriatal injection; single) attenuates neuronal death and improves cognitive and motor deficits in a rat model of Huntington's disease induced by 3-NP[6].
N6-Cyclohexyladenosine (1.5 mg/kg induction dose, followed by three 1.0 mg/kg doses every 6 hours for a total of 4 doses; i.p.; 4 times) does not show neuroprotective effects in a rat model of middle cerebral artery occlusion (MCAO), failing to reduce infarct volume and improve neurological function[7].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Adult male Sprague-Dawley rats (weight 180-220 g), 3-nitropropionic acid (3-NP)-induced Huntington's disease model[6]
Dosage: 6.25 nM/1 μL (dissolved in DMSO)
Administration: Intrastriatal injection, single administration, 45 min after 3-NP injection
Result: Significantly attenuated neuronal death in the striatum.
Improved cognitive and motor deficits as shown by increased time spent in the target quadrant in the Morris Water Maze test and increased fall off latency in the rotarod test.
Enhanced the activation of the PI3K/Akt/CREB/BDNF axis.
Increased pERK1/2 levels, attenuated neuroinflammatory and oxidative stress status.
Reduced the immunoreactivity of glial fibrillary acidic protein (GFAP).
Increased the number of intact neurons in the striatum.
Clinical Trial
Molecular Weight

349.38

Formula

C16H23N5O4
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

OC[C@@H]1[C@H]([C@H]([C@H](N2C=NC3=C2N=CN=C3NC4CCCCC4)O1)O)O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
Solvent & Solubility
In Vitro: 

DMSO : ≥ 100 mg/mL (286.22 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.8622 mL 14.3111 mL 28.6221 mL
5 mM 0.5724 mL 2.8622 mL 5.7244 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (7.16 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (7.16 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 99.98%

SDS (393 KB)

COA (253 KB) HNMR (189 KB) LCMS (333 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.8622 mL 14.3111 mL 28.6221 mL 71.5553 mL
5 mM 0.5724 mL 2.8622 mL 5.7244 mL 14.3111 mL
10 mM 0.2862 mL 1.4311 mL 2.8622 mL 7.1555 mL
15 mM 0.1908 mL 0.9541 mL 1.9081 mL 4.7704 mL
20 mM 0.1431 mL 0.7156 mL 1.4311 mL 3.5778 mL
25 mM 0.1145 mL 0.5724 mL 1.1449 mL 2.8622 mL
30 mM 0.0954 mL 0.4770 mL 0.9541 mL 2.3852 mL
40 mM 0.0716 mL 0.3578 mL 0.7156 mL 1.7889 mL
50 mM 0.0572 mL 0.2862 mL 0.5724 mL 1.4311 mL
60 mM 0.0477 mL 0.2385 mL 0.4770 mL 1.1926 mL
80 mM 0.0358 mL 0.1789 mL 0.3578 mL 0.8944 mL
100 mM 0.0286 mL 0.1431 mL 0.2862 mL 0.7156 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

N6-Cyclohexyladenosine Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

N6-Cyclohexyladenosine36396-99-3CHAAdenosine ReceptorPI3KAktEpigenetic Reader DomainP1 receptorPhosphoinositide 3-kinasePKBProtein kinase BHuntington's diseaseratMCAOoptic chiasmHep 3BInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
N6-Cyclohexyladenosine
Cat. No.:
HY-18939
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB) Italian - IT (393 KB) Portuguese - PT (393 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.